Adverse Event reporting information can be found in footer

Request a Meeting

About Propess

Propess is a single application, removable, controlled-release vaginal delivery system containing 10mg dinoprostone which is a prostaglandin E2. It is indicated for the initiation of cervical ripening in women from 38 weeks gestation as part of the induction of labour process.1


When Propess is inserted into the vagina, dinoprostone is released at a mean rate of approximately 0.3 mg/hour and drug release continues as long as the product is in situ in the vagina (for a period of up to 24 hours). The system is equipped with a withdrawal tape that facilitates convenient and easy removal when active labour begins or removal of the system is indicated.1

Propess was launched in the UK in 1995 and has since become one of the leading products in managing induction of labour, with over 12 million prescriptions dispensed globally between 1995 and 2017 2

Propess Key Messages

Learn More

  1. Ferring Pharmaceuticals. Propess Summary of Product Characteristics. October 2021  last viewed on 18/10/21
  2. Ferring Data on File 2019.
  3. R K Kallkat, E McMillan and H Cooper, Comparison of Dinoprostone slow release pessary (Propess) with gel (Prostin) for induction of labour at term-a randomised trial, Journal of Obstetrics and Gynaecology (2008)
  4. Calder AA and MacKenzie I, Review of Propess – a controlled release dinoprostone (prostaglandin E2) pessary, Journal of Obstetrics and Gynaecology (1997), Vol 17, Supplement 2, S53-S67
  5. Westgate J & Williams J.A. Evaluation of a controlled release vaginal prostaglandin E2 pessary with a retrieval system for the induction of labour, Journal of Obstetrics and Gynaecology (1994), Vol 14, Issue 3 May, 146-150
  6. Kelly AJ, Malik S, Smith L, Kavanagh J, Thomas J. Vaginal prostaglandin (PGE2 and PGF2a) for induction of labour at term. Cochrane Database of Systematic Reviews 2014,; (last viewed 18/10/21)
  7. Induction of Labour: 2021 Update, National Collaborating Centre for Women’s and Children’s Health, available at (last viewed 18/10/21)
  8. MacKenzie I and McKinlay E (1995). Paediatric follow-up study: Follow-up of infants delivered by spontaneous vaginal delivery, following prostaglandin E2 or oxytocin induction by caesarean section, In: Propess RS – A Clinical Review, edited by Calder A, Keirse M and Mackenzie I, pp. 37–39. Euromed Communications Ltd. England.

Job Code: UK-RMMH-2000023 - Date of preparation: March 2022


Our use of cookies

We use cookies (including third party cookies) to collect data while you use this website in order to make it work, keep it secure and comply with regulations. We’d also like your consent to use cookies so we can provide you with tailored content and advertising and analyse how you and other people use the website.

Select “On” to consent to our use of these cookies and continue to the website, or select “Off” to control which types of cookies we use. You can read more about cookies in our Privacy Policy.

Necessary cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytics cookies

We’d like to set Google Analytics cookies to help us to improve our website by collecting and reporting information on how you use it. The cookies collect information in away that does not directly identify anyone. For more information on how these cookies work, please see our Privacy Policy.